Riskpilot← Back to searchSign inGet full accessCytodelics AB
ABActiveOrg 5590504204Forskargatan 20 J Byggn 215Manufacture of other chemical products n.e.c. · NACE 2059Est. 20164 employees
Revenue 2024
SEK 2,8M
+26% vs 2023
EBITDA margin
7.0%
-9% vs 2023
Equity ratio
56.0%
Financial strength
Net profit 2024
SEK 89K
-30% vs 2023
| Revenue | SEK 2,8M | +26% |
| EBITDA | SEK 197K | -9% |
| Net profit | SEK 89K | -30% |
| Total assets | SEK 1,4M | +25% |
| Equity | SEK 783K | +13% |
| Employees | 4 | — |
Legal name
Cytodelics AB
Org number
5590504204
Legal form
Aktiebolag
NACE code
2059 · Manufacture of other chemical products n.e.c.
Founded
8 februari 2016
Share capital
SEK 51 000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Företaget ska bedriva handel med kemikalier, reagenser och teknisk utrustning och mjukvara för laboratorieverksamhet och klinisk verksamhet. Företaget ska även bedriva konsult- verksamhet inom dessa branscher.
Address
Forskargatan 20 J Byggn 215
Email
info@cytodelics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 947 | 1 296 | 1 383 | 2 247 | 2 834 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 169 | 371 | 226 | 216 | 197 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 169 | 371 | 226 | 216 | 197 |
| Net financials | 2 | — | — | — | 1 |
| Profit before tax | 125 | 277 | 168 | 162 | 147 |
| Tax | −27 | −57 | −35 | −34 | −58 |
| Net profit | 98 | 220 | 133 | 128 | 89 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 422 | 724 | 916 | 1 114 | 1 397 |
| Equity | 213 | 434 | 567 | 695 | 783 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 168 | 157 | 159 | 174 | 317 |
| Total debt | 168 | 157 | 159 | 174 | 317 |
EBITDA margin
7.0%
This company
15.8%
Market median
-56% vs market
20202024
Equity ratio
56.0%
This company
38.2%
Market median
+47% vs market
20202024
Return on equity
11.4%
This company
18.4%
Market median
+38% vs market
20202024
Net profit margin
3.1%
This company
8.1%
Market median
-62% vs market
20202024
Asset turnover
2.03×
This company
1.12×
Market median
+81% vs market
20202024
Debt / equity
0.78×
This company
0.62×
Market median
+26% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
BA Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Cytodelics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Björn Axel Olin | Chief Executive Officer | 0 companies |
| Jaromir Mikes | Board of Directors | 0 companies |
| Lucia Mikesova | Board of Directors | 0 companies |
| Lakshmi Kanth Tadepally | Board of Directors | 0 companies |
| Nyanja Brodin | Board of Directors | 0 companies |
| Petter Brodin | Chairman | 0 companies |